---
title: "European stocks \"Eleven Arhats\" | LVMH Group and L'Oréal have at least fallen over 3.6% this week, while AstraZeneca and Roche have at least risen by about 1.3%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/223941371.md"
description: "This week, LVMH Group and L'Oréal saw their stock prices decline by more than 3.6%, while AstraZeneca and Roche increased by approximately 1.3%. Specifically, LVMH fell by 3.79%, and L'Oréal dropped by 1.80%. AstraZeneca rose by 1.28% this week, and Roche increased by 1.47%. Other companies such as ASML Holding, Novo Nordisk, GlaxoSmithKline, SAP, Sanofi, and Nestlé also experienced varying degrees of ups and downs"
datetime: "2025-01-03T18:30:14.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/223941371.md)
  - [en](https://longbridge.com/en/news/223941371.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/223941371.md)
generator: "portal-rs"
---

# European stocks "Eleven Arhats" | LVMH Group and L'Oréal have at least fallen over 3.6% this week, while AstraZeneca and Roche have at least risen by about 1.3%

On Friday (January 3), ASML Holding's stock price in Amsterdam (ASML.NA) closed down 0.29% at €688.00, with a cumulative increase of 0.45% this week.  
 Novo Nordisk's stock price in Copenhagen (NOVOB.DC) closed down 0.20% at 637.50 Danish Krone, with a cumulative increase of 0.25% this week.  
 LVMH Group (MC.FP) closed down 3.79%, with a cumulative decrease of 3.82% this week.  
 L'Oréal (OR.FP) closed down 1.80%, with a cumulative decrease of 3.63% this week.  
 GlaxoSmithKline's stock price in London (GSK.LN) closed down 1.58%, with a cumulative decrease of 0.19% this week.  
 SAP (SAP.GR) closed down 1.55%, with a cumulative decrease of 2.05% this week.  
 Sanofi (SAN.FP) closed down 1.54%, with a cumulative decrease of 0.44% this week.  
 Nestlé (NESN.SW) closed down 0.24%, with a cumulative increase of 0.08% this week.  
 AstraZeneca (AZN.LN) closed down 0.34%, with a cumulative increase of 1.28% this week.  
 Roche Holding (ROG.SW) closed up 0.12%, with a cumulative increase of 1.47% this week.  
 Novartis (NOVN.SW) closed up 0.18%, with a cumulative increase of 0.41% this week

### Related Stocks

- [LVMUY.US](https://longbridge.com/en/quote/LVMUY.US.md)
- [RHHBY.US](https://longbridge.com/en/quote/RHHBY.US.md)
- [LRLCY.US](https://longbridge.com/en/quote/LRLCY.US.md)
- [AZN.US](https://longbridge.com/en/quote/AZN.US.md)
- [SAP.US](https://longbridge.com/en/quote/SAP.US.md)
- [NVO.US](https://longbridge.com/en/quote/NVO.US.md)
- [NSRGY.US](https://longbridge.com/en/quote/NSRGY.US.md)
- [NSRGF.US](https://longbridge.com/en/quote/NSRGF.US.md)
- [ASML.US](https://longbridge.com/en/quote/ASML.US.md)
- [GSK.US](https://longbridge.com/en/quote/GSK.US.md)
- [NVS.US](https://longbridge.com/en/quote/NVS.US.md)
- [SNYNF.US](https://longbridge.com/en/quote/SNYNF.US.md)
- [ROG.US](https://longbridge.com/en/quote/ROG.US.md)

## Related News & Research

- [Cramer's lightning round: 'I am not going to put my money on AstraZeneca'](https://longbridge.com/en/news/298373941.md)
- [AstraZeneca publishes transcript of ERS 2026 investor call and webcast](https://longbridge.com/en/news/298346504.md)
- [Health Rounds: AstraZeneca drug reduces lung disease flare-ups in late-stage trials](https://longbridge.com/en/news/298355260.md)
- [AstraZeneca's breast cancer drug fails in late-stage trial](https://longbridge.com/en/news/298768423.md)
- [Astrazeneca Secures FDA Approval for New Breast Cancer Treatment](https://longbridge.com/en/news/298345058.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**